Conducting clinical trials in Australia was critical for XWPharma, but without any Australian presence or experience, a highly proactive corporate services provider was key.
XWPharma is a clinical stage biopharmaceutical company developing best-in-class novel therapeutics to relieve the suffering of patients with neurological disorders. Their drug design methodology enables creation of novel molecules with uniquely beneficial drug properties that are amenable to achieving desired in vivo pharmacokinetic profiles and meaningful differentiation from existing drug therapies.
XWPharma wanted to conduct fast, high-quality and low-cost clinical trials in Australia. Having never conducted business in Australia, they did not know how to establish a company and do business in Australia.
We had never conducted business in Australia before. We didn’t even know the first step to opening up an Australian company.
With a clear and easy-to-understand process for supporting life sciences companies to conduct clinical trials in Australia, XWPharma chose Acclime to help them set up and run their trials. Colleagues in their industry recommended Acclime to XWPharma over larger providers due to our flat-fee pricing and expertise in this industry.
Acclime made the entire process from incorporating the company to the R&D rebate extremely streamlined and easy so we could 100% focus on clinical activities.
XWPharma ran successful Phase 1 clinical trials in Australia, and with our support, were able to take advantage of the R&D Tax Incentive with ease. The company is now looking to take their drug therapy to patients worldwide, and to initiate additional clinical trials in Australia over the coming years.
We successfully completed Phase 1 clinical trials in Australia and are now looking to take our drug therapy to patients worldwide.
William Xiang 向维林
Senior Director, Strategy & Operations